Lon Sar News Today

Sareum (LON:SAR – Get Rating)‘s stock had its “buy” rating restated by analysts at Peel Hunt in a report issued on Tuesday, MarketBeat.com reports. They presently have a GBX 304 ($3.78) price target on the stock. Peel Hunt’s target price suggests a potential upside of 133.85% from the stock’s previous close. Sareum Price Performance Shares […]

Sareum Holdings plc (LON:SAR – Get Rating) shares crossed above its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of GBX 111.19 ($1.37) and traded as high as GBX 124 ($1.53). Sareum shares last traded at GBX 117.50 ($1.45), with a volume of 23,004 shares changing […]

Sareum Holdings plc (LON:SAR – Get Rating) shares passed above its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of GBX 107.93 ($1.34) and traded as high as GBX 122.66 ($1.53). Sareum shares last traded at GBX 120.50 ($1.50), with a volume of 14,994 shares traded. […]

Follow John on: A look at some of the major movers in London on Tuesday M&C Saatchi PLC (LON:SAA) climbed 12% to 143.5p after it raised full-year guidance after the first four months of the year exceeded expectations. The advertising agency said new business performance has been robust. The company also announced it has entered into a new revolving credit facility. 10.00am: Powerhouse surges as its partner chooses site for second plastic to hydrogen facility Powerhouse Energy Group PLC (LON:PHE...

Follow John on: A look at some of the major movers in London on Tuesday Shefa Gems Ltd (LON:SEFA), up 56% at 3.5p, had a sparkling day after it announced a sharp change of direction. Previously the company has been focused on exploration and development of multi-gemstone mining projects in Israel but it wants to distribute the companys current mining business to all of the companys existing shareholders via a dividend in specie, raise news funds and look for acquisitions in the web technology a...

25 May 2021 | 09:39am StockMarketWire.com - Specialist drug developer Sareum said the pandemic had caused further delays to the development of a treatment for autoimmune diseases. The company had last month announcing that the pandemic continued to impact contract research organisations it was working with to complete preclinical development of SDC-1801 for autoimmune disease. While initially the impact on development timelines was minimal, it has increased and is causing further delays to th...

23 April 2021 | 07:56am StockMarketWire.com - Drug development firm Sareum has reported a half-annual loss on ordinary activities for the six months ended 31 December 2020 of £0.55m. It comes after the firm experienced a 2019 loss of £0.61m, however, the firm has welcomed positive product developments. Cash at the period end was £1.30 million versus £1.80 million as of 30 June 2020 and £1.00 million as of 31 December 2019. R&D Tax Credit of £0.13 million was received in January 2021, with...

Sareum welcomes launch of UK grant for Covid-19 treatments